Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vernakalant vs Ibutilide in recent-onset atrial fibrillation
NCT01447862Phase 4Completed
- Sponsor
- Medical University of Vienna
- Start
- Oct 2011
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of vernakalant in Atrial fibrillation (AFib), sponsored by Medical University of Vienna. Primary endpoint: Time in minutes until conversion to sinus rhythm at 90 minutes. Started Oct 2011; status: completed.
02
Drugs
vernakalant
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on NCT01447862.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01447862.